Posted on

cbd en argentina

Cbd en argentina

Faced with this situation, it is necessary to take into consideration the current state of cannabis regulation in both countries to understand a little the advances that have been made in legislative and administrative matters:

In this way, and in the current situation, the main objective of the agreements is to be able to generate opportunities for exchange and traffic, not only for business but also for assets, products, raw materials, and knowledge – research and development – between Brazil and Argentina.


Last February, an agreement was signed between the Argentine and Brazilian Cannabis Chambers in order to strengthen bilateral agreements to generate business between both countries, taking into consideration the fact that Argentina has sanctioned the cannabis law, allowing it the possibility of – under certain conditions – promoting the research, development, production, and commercialization of products derived from cannabis for medicinal use; while in Brazil, the sanitary authority -ANVISA- allows the manufacture of products for medicinal use, but cultivation is still prohibited as well as recreational use.


With this resolution issued, the registration of cultivars of the Cannabis sativa L. species is authorized before the National Registry of Cultivars and/or the National Registry of the Property of Cultivars of the NATIONAL INSTITUTE OF SEEDS.

Objective: We report our preliminary findings regarding effectiveness, safety, and tolerability of cannabidiol (CBD) added to antiepileptic therapy in a cohort of children with drug-resistant epileptic encephalopathies (EEs) with a mean follow-up of 8.5 months (range, 3-12 months).

Conclusion: In children with drug-resistant EEs, CBD oil as an adjuvant therapy to antiepileptic therapy seems safe, well tolerated, and effective.

Results: Fifty patients were enrolled between October 2018 and October 2019, 49 of whom had a follow-up of at least 3 months at the time this interim analysis was performed. Mean age at enrollment was 10.5 years (range 2-16). Median age at first seizure was 7 months. Up to the last visit of each patient (follow-up 3-12 months) 39/49 children (80 %) had responded to treatment with a decrease in seizure frequency. Overall, 77.6 % of the patients had a seizure reduction of at least 25 %, 73.5 % had a ≥ 50 % reduction, and 49 % had a ≥ 75 % reduction. Mean monthly seizure frequency was reduced from 959 to 381 (median decrease from 299 to 102, range, 38-1900; median decrease 66 %, p < 0.001). All adverse effects were mild or moderate. The most common adverse effect was drowsiness (in 32 %), usually reversed by adjusting clobazam dose (in 12 children).